Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rucaparib + bevacizumab + atezolizumab
- Development stage
- Phase 2
- Lead developer
- Clovis Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (rucaparib), Intravenous (bevacizumab), Intravenous (atezolizumab)
01
Overview
**Rucaparib + bevacizumab + atezolizumab** is an investigational, non-chemotherapy triple combination regimen being studied for recurrent or persistent endometrial cancer. - **Rucaparib** is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair, leading to apoptosis in tumor cells deficient in homologous recombination repair. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor blood supply. - **Atezolizumab** is a monoclonal antibody that binds PD-L1, blocking its interaction with PD-1 and B7.1, thereby enhancing antitumor immune response. This triplet has demonstrated clinically meaningful antitumor activity and tolerable toxicity in phase II clinical trials for recurrent or persistent endometrial carcinoma, especially among mismatch repair-deficient (MMRd) patients[9][10][8][7].
- Other names
- rucaparib + bevacizumab + atezolizumab
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on rucaparib + bevacizumab + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rucaparib + bevacizumab + atezolizumab.